Intraventricular or intrathecal colistin for the treatment of central nervous system infections caused by multidrug-resistant Gram-negative bacteria

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Central nervous system infections caused by Gram-negative bacteria susceptible only to colistin are rare but life-threatening and increasing in prevalence. Given the current antibiotic development pipeline it is likely that the paucity of therapeutic options will continue for the next years. Colistin is an amphipathic bactericidal antibiotic which is administered systemically as colistin methanesulfonate (also known as colistimethate sodium). Colistin methanesulfonate is the inactive prodrug, and in cerebrospinal fluid undergoes spontaneous hydrolysis to colistin (the active form with antimicrobial activity). In this review, we describe and evaluate the clinical and experimental data supporting the use of intraventricular (IVT) or intrathecal (IT) colistin against multidrug-resistant Gram-negative infections of the central nervous system, describe the permeability of the blood-brain barrier to colistin, the pharmacokinetics of colistin after IVT administration of colistin methanesulfonate, its anti-endotoxin activity, discuss the opportunity to administer colistin intraventricularly or intrathecally and the dose regimen, and provide recommendations based on the available evidence.

Original languageEnglish
Pages (from-to)471-478
Number of pages8
JournalExpert Review of Anti-Infective Therapy
Volume12
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Colistin
Central Nervous System Infections
Gram-Negative Bacteria
Anti-Bacterial Agents
Prodrugs
Blood-Brain Barrier
Endotoxins
Cerebrospinal Fluid
Permeability
Hydrolysis
Pharmacokinetics

Keywords

  • bloodbrain barrier
  • cerebrospinal fluid
  • colistin
  • intraventricular
  • meningitis
  • ventriculitis

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology
  • Medicine(all)

Cite this

@article{7b4ab09ee46a420f93697babb68b59c6,
title = "Intraventricular or intrathecal colistin for the treatment of central nervous system infections caused by multidrug-resistant Gram-negative bacteria",
abstract = "Central nervous system infections caused by Gram-negative bacteria susceptible only to colistin are rare but life-threatening and increasing in prevalence. Given the current antibiotic development pipeline it is likely that the paucity of therapeutic options will continue for the next years. Colistin is an amphipathic bactericidal antibiotic which is administered systemically as colistin methanesulfonate (also known as colistimethate sodium). Colistin methanesulfonate is the inactive prodrug, and in cerebrospinal fluid undergoes spontaneous hydrolysis to colistin (the active form with antimicrobial activity). In this review, we describe and evaluate the clinical and experimental data supporting the use of intraventricular (IVT) or intrathecal (IT) colistin against multidrug-resistant Gram-negative infections of the central nervous system, describe the permeability of the blood-brain barrier to colistin, the pharmacokinetics of colistin after IVT administration of colistin methanesulfonate, its anti-endotoxin activity, discuss the opportunity to administer colistin intraventricularly or intrathecally and the dose regimen, and provide recommendations based on the available evidence.",
keywords = "bloodbrain barrier, cerebrospinal fluid, colistin, intraventricular, meningitis, ventriculitis",
author = "Roberto Imberti and Iotti, {Giorgio Antonio} and Mario Regazzi",
year = "2014",
doi = "10.1586/14787210.2014.896740",
language = "English",
volume = "12",
pages = "471--478",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Intraventricular or intrathecal colistin for the treatment of central nervous system infections caused by multidrug-resistant Gram-negative bacteria

AU - Imberti, Roberto

AU - Iotti, Giorgio Antonio

AU - Regazzi, Mario

PY - 2014

Y1 - 2014

N2 - Central nervous system infections caused by Gram-negative bacteria susceptible only to colistin are rare but life-threatening and increasing in prevalence. Given the current antibiotic development pipeline it is likely that the paucity of therapeutic options will continue for the next years. Colistin is an amphipathic bactericidal antibiotic which is administered systemically as colistin methanesulfonate (also known as colistimethate sodium). Colistin methanesulfonate is the inactive prodrug, and in cerebrospinal fluid undergoes spontaneous hydrolysis to colistin (the active form with antimicrobial activity). In this review, we describe and evaluate the clinical and experimental data supporting the use of intraventricular (IVT) or intrathecal (IT) colistin against multidrug-resistant Gram-negative infections of the central nervous system, describe the permeability of the blood-brain barrier to colistin, the pharmacokinetics of colistin after IVT administration of colistin methanesulfonate, its anti-endotoxin activity, discuss the opportunity to administer colistin intraventricularly or intrathecally and the dose regimen, and provide recommendations based on the available evidence.

AB - Central nervous system infections caused by Gram-negative bacteria susceptible only to colistin are rare but life-threatening and increasing in prevalence. Given the current antibiotic development pipeline it is likely that the paucity of therapeutic options will continue for the next years. Colistin is an amphipathic bactericidal antibiotic which is administered systemically as colistin methanesulfonate (also known as colistimethate sodium). Colistin methanesulfonate is the inactive prodrug, and in cerebrospinal fluid undergoes spontaneous hydrolysis to colistin (the active form with antimicrobial activity). In this review, we describe and evaluate the clinical and experimental data supporting the use of intraventricular (IVT) or intrathecal (IT) colistin against multidrug-resistant Gram-negative infections of the central nervous system, describe the permeability of the blood-brain barrier to colistin, the pharmacokinetics of colistin after IVT administration of colistin methanesulfonate, its anti-endotoxin activity, discuss the opportunity to administer colistin intraventricularly or intrathecally and the dose regimen, and provide recommendations based on the available evidence.

KW - bloodbrain barrier

KW - cerebrospinal fluid

KW - colistin

KW - intraventricular

KW - meningitis

KW - ventriculitis

UR - http://www.scopus.com/inward/record.url?scp=84896333891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896333891&partnerID=8YFLogxK

U2 - 10.1586/14787210.2014.896740

DO - 10.1586/14787210.2014.896740

M3 - Article

VL - 12

SP - 471

EP - 478

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 4

ER -